{"id":192124,"date":"2023-02-16T00:00:00","date_gmt":"2023-02-15T23:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/covid-19-vaccin-adapte-pfizer-egalement-utilise-pour-la-primo-vaccination\/"},"modified":"2023-02-16T00:00:00","modified_gmt":"2023-02-15T23:00:00","slug":"covid-19-vaccin-adapte-pfizer-egalement-utilise-pour-la-primo-vaccination","status":"publish","type":"post","link":"https:\/\/r.cbip.be\/fr\/covid-19-vaccin-adapte-pfizer-egalement-utilise-pour-la-primo-vaccination\/","title":{"rendered":"COVID-19 : vaccin adapt\u00e9 Pfizer \u00e9galement utilis\u00e9 pour la primo-vaccination"},"content":{"rendered":"<p>La Conf&eacute;rence Interminist&eacute;rielle Belge (CIM) a d&eacute;cid&eacute; le 18 janvier 2023 que le vaccin bivalent BA.4-5 <a href='https:\/\/www.cbip.be\/fr\/chapters\/13?frag=8901373'><strong>(Comirnaty Original\/Omicron BA.4-5&reg;)<\/strong><\/a> pouvait &eacute;galement &ecirc;tre utilis&eacute; pour la <strong>primo-vaccination &agrave; partir de l&rsquo;&acirc;ge de 12 ans<\/strong>. La CIM s&rsquo;appuie sur <a href='https:\/\/www.ema.europa.eu\/en\/news\/etf-concludes-bivalent-original-omicron-ba4-5-mrna-vaccines-may-be-used-primary-vaccination'>un avis favorable de la Task Force d&rsquo;urgence de l&rsquo;EMA &agrave; ce propos<\/a>.<span class='folia-referentie-nummer'><strong><sup>1<\/sup><\/strong><\/span><br \/> Le vaccin bivalent BA.4-5 de Pfizer cible&nbsp;le virus original du SARS-CoV-2 + les sous-variants Omicron BA.4-5.<\/p>\n<p>Le <b>vaccin bivalent BA.4-5 (Comirnaty Original\/Omicron BA.4-5&reg;) <\/b>peut &ecirc;tre <b>command&eacute;<\/b> pour la primo-vaccination et la vaccination de rappel contre la COVID-19 &agrave; partir de l&rsquo;&acirc;ge de 12 ans. Le vaccin original Pfizer (Comirnaty&reg;) ne peut plus &ecirc;tre command&eacute;.<\/p>\n<div class='detailed-content'>En ce qui concerne la Flandre&#x002C; nous pouvons nous r&eacute;f&eacute;rer &agrave; <a href='https:\/\/www.laatjevaccineren.be\/informatie-voor-artsen-en-apothekers'>laatjevaccineren.be<\/a> &gt; document &laquo;&nbsp;SOP inkanteling reguliere trajectory versie 4.0&nbsp;&raquo; (version 24\/01\/23) pour les d&eacute;tails concernant les d&eacute;lais de commande des vaccins COVID-19&#x002C; la proc&eacute;dure de commande et les vaccins qui peuvent &ecirc;tre command&eacute;s et utilis&eacute;s pour les enfants et adultes.<\/div>\n<p>Malgr&eacute; la recommandation de l&rsquo;EMA&#x002C; la primo-vaccination avec le vaccin Comirnaty Original\/Omicron BA.4-5&reg; est une<b> utilisation off-label&nbsp;<\/b>: la seule indication du RCP est l&rsquo;utilisation comme vaccination de rappel contre la COVID-19 &agrave; partir de l&rsquo;&acirc;ge de 12 ans (situation au 30\/01\/23).<\/p>\n<p>Nous renvoyons au <a href='https:\/\/www.cbip.be\/fr\/chapters\/13?frag=8901373'>R&eacute;pertoire 12.1.1.15.<\/a> pour les d&eacute;tails concernant les vaccins contre la COVID-19. Une vaccination de base et au moins un rappel suppl&eacute;mentaire sont indiqu&eacute;s pour tous les groupes &agrave; haut risque. Concernant la vaccination des enfants et des adolescents &agrave; haut risque de COVID-19 s&eacute;v&egrave;re&#x002C; voir <a href='https:\/\/www.cbip.be\/fr\/articles\/3663?folia=3658'>Folia ao&ucirc;t 2021<\/a> (12-17 ans)&#x002C; <a href='https:\/\/www.cbip.be\/fr\/articles\/3746?folia=3740'>Folia janvier 2022<\/a> (5-11 ans) et <a href='https:\/\/www.cbip.be\/fr\/articles\/3954?folia=3941'>Folia d&eacute;cembre 2022<\/a> (enfants de 6 mois &agrave; 5 ans).<\/p>\n<h2> Sources sp&eacute;cifiques<\/h2>\n<p><span class='folia-referentie-tekst'><span class='folia-referentie-nummer'>1&nbsp;<\/span>EMA. ETF concludes that bivalent original\/Omicron BA.4-5 mRNA vaccines may be used for primary vaccination. <a href='https:\/\/www.ema.europa.eu\/en\/news\/etf-concludes-bivalent-original-omicron-ba4-5-mrna-vaccines-may-be-used-primary-vaccination'>News 06\/12\/22<\/a>.<\/span><\/p>\n<h2>Sources g&eacute;n&eacute;rales<\/h2>\n<p>&#8211;&nbsp;<a href='https:\/\/www.laatjevaccineren.be\/informatie-voor-artsen-en-apothekers'>https:\/\/www.laatjevaccineren.be\/informatie-voor-artsen-en-apothekers<\/a> &gt; document &ldquo;SOP inkanteling reguliere traject&rdquo; (version 24\/01\/23)<br \/> &#8211;&nbsp;<a href='https:\/\/www.vaccinnet.be\/Vaccinnet\/welkom.do'>https:\/\/www.vaccinnet.be\/Vaccinnet\/welkom.do<\/a> (consult&eacute; le 25\/01\/23)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Conf&eacute;rence Interminist&eacute;rielle Belge (CIM) a d&eacute;cid&eacute; le 18 janvier  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,14914],"tags":[20213],"class_list":["post-192124","post","type-post","status-publish","format-standard","hentry","category-actualites","category-2023-fr","tag-import_tags"],"_links":{"self":[{"href":"https:\/\/r.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/192124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/r.cbip.be\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/r.cbip.be\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/r.cbip.be\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/r.cbip.be\/fr\/wp-json\/wp\/v2\/comments?post=192124"}],"version-history":[{"count":0,"href":"https:\/\/r.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/192124\/revisions"}],"wp:attachment":[{"href":"https:\/\/r.cbip.be\/fr\/wp-json\/wp\/v2\/media?parent=192124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/r.cbip.be\/fr\/wp-json\/wp\/v2\/categories?post=192124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/r.cbip.be\/fr\/wp-json\/wp\/v2\/tags?post=192124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}